glp-1 rheumatoid arthritis and Inflammation: How These Drugs Ease GLP-1s may reduce cardiovascular risk

Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Italy: a retrospective cohort study

TZP was superior to dulaglutide in GC and reduction of BW and the safety report of TZP was coherent with that of dulaglutide (80)

Multiple systematic reviews and meta-analyses have been conducted, with most indicating no significant difference in fracture risk between GLP-1Ra and placebo or other anti-diabetic medications [75,76,77]

[17] [18] Additional risk factors include: Female sex and pregnancy history : Women, particularly those who have been pregnant, have higher baseline gallstone risk Age over 40 years : Gallbladder disease incidence increases with age Obesity : Higher BMI correlates with increased gallstone prevalence Diabetes : Type 2 diabetes itself is associated with gallbladder dysfunction Rapid weight cycling : History of repeated weight loss and regain Certain ethnicities : Native American and Hispanic populations have higher gallstone rates [23] [24] Family history : Genetic predisposition to gallbladder disease Estrogen therapy : May increase cholesterol saturation in bile Patients with multiple risk factors should engage in thorough discussion with their healthcare provider about symptom awareness

Available from: Karagiannis T, Tsapas A, Athanasiadou E, Avgerinos I, Liakos A, Matthews DR et al (2021) GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis